• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient.

作者信息

Busutti Marco, Cingolani Alessandra, Natali Filippo, Mattiotti Maria, Grandinetti Valeria, Baraldi Olga, Comai Giorgia, Candoli Piero, La Manna Gaetano

机构信息

Nephrology, Dialysis and Transplant Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Interventional Pulmonology Unit, IRCCS Policlinico Sant'Orsola, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

出版信息

J Nephrol. 2022 May;35(4):1275-1278. doi: 10.1007/s40620-022-01298-w. Epub 2022 Mar 14.

DOI:10.1007/s40620-022-01298-w
PMID:35286598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8919162/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/b5b7a39e5f90/40620_2022_1298_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/d0b0ff1b674d/40620_2022_1298_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/d1d0c54589a8/40620_2022_1298_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/b5b7a39e5f90/40620_2022_1298_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/d0b0ff1b674d/40620_2022_1298_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/d1d0c54589a8/40620_2022_1298_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b01/8919162/b5b7a39e5f90/40620_2022_1298_Fig3_HTML.jpg

相似文献

1
Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient.肾移植受者停用依维莫司后出现与依维莫司相关的肺泡出血复发。
J Nephrol. 2022 May;35(4):1275-1278. doi: 10.1007/s40620-022-01298-w. Epub 2022 Mar 14.
2
Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.依维莫司治疗肾移植受者BK病毒肾病：一项前瞻性对照研究。
J Nephrol. 2021 Apr;34(2):531-538. doi: 10.1007/s40620-020-00777-2. Epub 2020 Jun 12.
3
Effect of Age on Conversion to Everolimus with Calcineurin Inhibitor Minimization at A Late Post-Transplant Stage.
Urol J. 2018 Sep 26;15(5):266-271. doi: 10.22037/uj.v0i0.4326.
4
Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data.稳定的ABO血型不相容肾移植受者从霉酚酸酯转换为依维莫司的初步转换研究：1年随访数据分析
Exp Clin Transplant. 2019 Apr;17(2):190-195. doi: 10.6002/ect.2017.0200. Epub 2018 Sep 4.
5
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.一项开放性、随机试验表明，依维莫司联合他克莫司或环孢素与标准免疫抑制方案在肾移植初治患者中的疗效相当。
Kidney Int. 2019 Jul;96(1):231-244. doi: 10.1016/j.kint.2019.01.041. Epub 2019 Feb 27.
6
Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.肾移植患者接受依维莫司治疗时，晚期皮肤鳞状细胞癌对西米普利单抗的快速应答。
Clin Exp Dermatol. 2022 Mar;47(3):608-609. doi: 10.1111/ced.15018. Epub 2021 Dec 11.
7
The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.在接受依维莫司和降低剂量环孢素治疗的肾移植受者中，癌症风险可能降低。
Kidney Int. 2017 Apr;91(4):954-963. doi: 10.1016/j.kint.2016.11.008. Epub 2017 Jan 18.
8
An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.依维莫司在成人实体器官移植受者中的疗效和安全性概述。
Transplant Rev (Orlando). 2022 Jan;36(1):100655. doi: 10.1016/j.trre.2021.100655. Epub 2021 Sep 24.
9
Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.使用依维莫司为基础的免疫抑制来降低肾移植后巨细胞病毒感染的发生率。
Exp Clin Transplant. 2016 Aug;14(4):361-6. doi: 10.6002/ect.2015.0292. Epub 2016 Apr 4.
10
Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients.依维莫司与霉酚酸酯方案用于小儿肾移植受者的疗效和安全性比较
PLoS One. 2015 Sep 25;10(9):e0135439. doi: 10.1371/journal.pone.0135439. eCollection 2015.

本文引用的文献

1
Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature.危及生命的依维莫司相关性肺炎：一例病例报告及文献综述
Transplant Proc. 2018 Apr;50(3):933-938. doi: 10.1016/j.transproceed.2017.12.003. Epub 2018 Mar 24.
2
Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.实体器官移植受者中与mTOR抑制剂相关的间质性肺病：依维莫司大型III期临床试验项目的结果及文献综述
J Transplant. 2014;2014:305931. doi: 10.1155/2014/305931. Epub 2014 Dec 18.
3
Pulmonary toxicity in a renal transplant recipient treated with amiodarone and everolimus: a case of hypothetical synergy and a proposal for a screening protocol.
胺碘酮和依维莫司治疗的肾移植受者的肺毒性：一例假设的协同作用及筛查方案建议
Case Rep Nephrol Urol. 2014 Apr 12;4(1):75-81. doi: 10.1159/000362361. eCollection 2014 Jan.